AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...

CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously ...

A University of Missouri scientist develops a cancer “flashlight” that helps identify which patients are most likely to ...

Hello, everyone. Good evening and good morning. Thank you for joining HUTCHMED 2025 R&D Day event. For your reference, you can go to our website to download today's presentation slides. The ...

The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...